Brit J Cancer:系统的化学筛选鉴定的disulfiram能够增强膀胱癌对顺铂的敏感性

2019-11-15 AlexYang MedSci原创

由于化疗抗性的产生,标准的吉西他滨与顺铂(GC)化疗对晚期膀胱癌的治疗效果有限,增强对GC的敏感性也是一个临床挑战。最近,有研究人员对已知的化学药物和可替代药物进行了高通量筛选,共包括了2098种化合物。研究人员对那些能够增强GC效果的化学药物进行了筛选。研究发现,在多个细胞系中,一种抗酒精药物disulfiram(DSF)能够与顺铂表现出协同效应,而与吉西他滨并没有上述效应。共同施加DSF与GC

由于化疗抗性的产生,标准的吉西他滨与顺铂(GC)化疗对晚期膀胱癌的治疗效果有限,增强对GC的敏感性也是一个临床挑战。

最近,有研究人员对已知的化学药物和可替代药物进行了高通量筛选,共包括了2098种化合物。研究人员对那些能够增强GC效果的化学药物进行了筛选。研究发现,在多个细胞系中,一种抗酒精药物disulfiram(DSF)能够与顺铂表现出协同效应,而与吉西他滨并没有上述效应。共同施加DSF与GC能够影响顺铂输出转运蛋白ATP7A的细胞定位,增加DNA-铂加合物并促进细胞凋亡。体内能够稳定DSF的微胞DSF纳米粒子(DSF-NP)能够增强顺铂在患者来源和基于细胞异种种植模型中的抑制作用,并且没有严重的副作用。药物敏感性评估系统能够鉴定那些可以从DSF结合顺铂治疗中受益的案例。

最后,研究人员指出,他们的研究强调了药物再定位在增强化疗抗癌效果中的优势。将DSF重新利用作为化疗增敏剂也许能够增强治疗效果,降低花费。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1737624, encodeId=cfdc1e37624f5, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 04 15:04:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013096, encodeId=59cd20130963d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Mar 29 02:04:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388470, encodeId=97c213884e0f8, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584431, encodeId=85f01584431ea, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375211, encodeId=71813e521186, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:49:34 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039956, encodeId=6911103995609, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Nov 15 17:04:00 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1737624, encodeId=cfdc1e37624f5, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 04 15:04:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013096, encodeId=59cd20130963d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Mar 29 02:04:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388470, encodeId=97c213884e0f8, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584431, encodeId=85f01584431ea, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375211, encodeId=71813e521186, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:49:34 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039956, encodeId=6911103995609, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Nov 15 17:04:00 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1737624, encodeId=cfdc1e37624f5, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 04 15:04:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013096, encodeId=59cd20130963d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Mar 29 02:04:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388470, encodeId=97c213884e0f8, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584431, encodeId=85f01584431ea, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375211, encodeId=71813e521186, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:49:34 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039956, encodeId=6911103995609, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Nov 15 17:04:00 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1737624, encodeId=cfdc1e37624f5, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 04 15:04:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013096, encodeId=59cd20130963d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Mar 29 02:04:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388470, encodeId=97c213884e0f8, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584431, encodeId=85f01584431ea, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375211, encodeId=71813e521186, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:49:34 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039956, encodeId=6911103995609, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Nov 15 17:04:00 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1737624, encodeId=cfdc1e37624f5, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 04 15:04:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013096, encodeId=59cd20130963d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Mar 29 02:04:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388470, encodeId=97c213884e0f8, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584431, encodeId=85f01584431ea, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375211, encodeId=71813e521186, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:49:34 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039956, encodeId=6911103995609, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Nov 15 17:04:00 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2019-11-15 14794e5bm67(暂无昵称)

    非常精彩,受益非浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1737624, encodeId=cfdc1e37624f5, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Wed Dec 04 15:04:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013096, encodeId=59cd20130963d, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Mar 29 02:04:00 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388470, encodeId=97c213884e0f8, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584431, encodeId=85f01584431ea, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Nov 17 05:04:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375211, encodeId=71813e521186, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:49:34 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039956, encodeId=6911103995609, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Nov 15 17:04:00 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2019-11-15 留走人康

    膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效

    0

相关资讯

J Hepatol:饮食和化学药物诱导的疾病快速进展的NASH模型

研究表明,NASH小鼠模型显示了晚期肝纤维化和HCC的快速进展,并模仿了人类NASH的组织学、免疫学和转录的特征,这表明它将成为临床前药物测试的一个有用的实验工具

刘昌孝院士:生物医药全面开花

个体化治疗和免疫疗法成创新热点 2014年,美国食品药品监督管理局(FDA)审批的个性化药物仅占21%,2015年增长至28%,其中抗肿瘤药物增长至35%。这与业界对个性化药物优先审批有关。针对遗传性罕见病的新药的批准数量也在扩增,这反映了基因组学和个性化药物的进步。 数据分析认为,2016年,新研发的药物40%以上可能为个性化药物,今后这一比例还将会持续上升。2014年,